EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients

Hepatitis C Clinical Trial

Official title:

A Randomized, Double-Blind, Pbo-Controlled, Study of EDP-494 to Evaluate the Safety and PK of SAD/FE in Healthy Subjects and MAD in Healthy and in Subjects With CHC Infection (POC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02652377
• Other study ID #: EDP-494-001
• Status: Completed
• Phase: Phase 1
• First received: January 6, 2016
• Last updated: January 20, 2017
• Start date: January 10, 2016
• Est. completion date: December 27, 2016

Study information

• Verified date: January 2017
• Source: Enanta Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized, double-blind study will assess the safety, pharmacokinetics and efficacy of a single and multiple dose(s) of orally QD administered EDP-494 in healthy volunteers (HV) and in treatment-naive subjects with GT1/3 chronic hepatitis C (CHC) infection.

Description:

The first phase explores single ascending doses of EDP-494 (active drug or placebo) in healthy subjects. A 'fasted' vs 'fed' two-part cohort will also assess food effect.

The second phase involves multiple ascending doses (active drug or placebo) for 14 days in healthy subjects.

The third, proof of concept, phase will assess two different doses for 14 days each in Hepatitis C patients.

Each cohort within each phase will consist of 8 subjects randomized to either EDP-494 or placebo in a 3 to 1 ratio, with the exception of the food effect cohort, which will consist of 10 subjects randomised in a 4 to 1 ratio.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: December 27, 2016
• Est. primary completion date: December 27, 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria for Healthy Volunteers (SAD and MAD Phases):

• Healthy male and female subjects of any ethnic origin between the ages of 18 and 55 years, inclusive.

• Female subjects must be of non-childbearing potential.

• All male participants who have not had a vasectomy must use effective contraception from Day -1 to 90 days after their last dose of study drug.

• Body mass index of 18 to 30 kg/m2 with a minimum body weight of 50 kg.

• An informed consent document signed and dated by the subject.

Exclusion Criteria for Healthy Volunteers (SAD and MAD Phases):

• Clinically relevant evidence or history of illness or disease

• Pregnant or nursing females.

• History of febrile illness within 7 days prior to the first dose of study drug or subjects with evidence of active infection.

• A positive urine drug screen at screening or Day -1.

• Any condition possibly affecting drug absorption (e.g., gastrectomy).

• History of regular alcohol consumption

• Participation in a clinical trial within 30 days prior to study drug administration.

• Use of prescription drugs, non-prescription drugs, dietary supplements, herbal supplements, hormonal therapy/replacement or CYP3A4 substrates, inducers and inhibitors within 14 days prior to the first dose of study medication

Inclusion Criteria for HCV-Infected Subjects (POC Phase):

• Males and females aged 18 years and less than 70 years.

• Female subjects must be of non-childbearing potential.

• All male participants who have not had a vasectomy must use effective contraception from Day -1 to 90 days after their last dose of study drug.

• Body mass index of 18 to 36 kg/m2 with a minimum body weight of 50 kg.

• Treatment naïve subjects with chronic HCV infection,

• HCV GT1 (including 1a, 1b, or mixed subtypes of GT1) or GT3.

• HCV RNA =100,000 IU/mL at screening.

• An informed consent document signed and dated by the subject.

Exclusion Criteria for HCV-Infected Subjects (POC Phase):

• Women of childbearing potential (WOCBP).

• Pregnant or nursing females.

• History of febrile illness within 7 days prior to the first dose of study drug.

• A positive urine drug screen at screening unless on an approved prescription.

• History of participation in a clinical trial with a polymerase inhibitor or previous treatment with a polymerase inhibitor, where at least one dose of the polymerase inhibitor was consumed. Subjects who were dosed with placebo on a clinical trial may be enrolled in this study.

• Clinically significant electrocardiogram abnormalities or QTcF greater than 450 msec for males and 470 msec for females at either screening or baseline, or any prior history of QT abnormality.

• Co-infection with HIV-1, HIV-2 or HBV.

• Have clinically significant laboratory abnormalities at screening:

• Absolute neutrophil count (ANC) < 1500/mm2 (1.5 x 109L)

• Platelets <90,000/mm2 (90 x 109L)

• Hemoglobin < 13g/dL for males and < 12g/dL for females

• Serum creatinine >1.5 x upper limit of normal (ULN) or creatinine clearance < 50 mL/min; estimated by the cockcroft -Gault formula [(140-age) x weight (kg)/72 x serum creatinine (mg/dL), if female multiply by 0.85]

• Total bilirubin greater than the ULN

• Serum alanine transaminase (ALT) > 5 x ULN

• Serum aspartate aminotransferase (AST) > 5 x ULN

• Alkaline phosphatase > 1.25 x ULN

• Pancreatic Amylase > 1.1 x ULN

• Alpha fetoprotein (AFP) > 50 ng/mL unless a liver imaging study (CT, MRI) shows no clinically significant lesions within 6 months prior to the first dose of study drug.

• Patients with evidence of cirrhosis; cirrhosis is defined as any one of the following: a) any biopsy showing cirrhosis (Knodell score <3, Metavir score <3, Ishak score <4); b) Fibroscan evaluation within 6 months prior to screening with a liver stiffness score of ><12.5 kPa.

• Other significant, unstable or uncontrolled medical history, such as neurological, endocrine, malignancy, renal, psychiatric, respiratory, cardiac, gastrointestinal, allergic, immunological, etc. disease.

• Use of concomitant medications, including vitamins or herbal and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis C

Intervention

Drug:
• EDP-494
10, 100 and 200 mg capsules
• Placebo
placebo to match EDP-494

Locations

Country	Name	City	State
New Zealand	Auckland Clinical Studies Ltd	Auckland

Sponsors (2)

Lead Sponsor	Collaborator
Enanta Pharmaceuticals	Novotech (Australia) Pty Limited

Country where clinical trial is conducted

New Zealand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Composite number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG, and abnormal clinical laboratory results administered to healthy volunteers and multiple doses of EDP-494	Tabulation of the number and frequency of treatment emergent adverse events, physical examination findings, abnormal vital signs, 12 lead ECG, echo and abnormal clinical laboratory results (including chemistry, hematology, and urine).; Administered to healthy volunteers and multiple doses of EDP-494 administered to healthy volunteers and subjects with Chronic Hepatitis C (CHC) genotype 1 and 3 infection	From screening and baseline to the 4 week follow-up visit
Secondary	Cmax	EDP-494 and metabolites	0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, 72 (Day 4), 96 (Day 5), 120 (Day 6)*, 144 (Day 7) and 168 (Day 8) hrs postdose
Secondary	Cmax	EDP-494 and metabolites	Day 1: 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15 hrs; Days 2, 3, 5, 7, 9, 12: 0 (Predose); Day 14: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, 72, 96, 120, 144 and 168 hrs postdose
Secondary	AUC	EDP-494 and metabolites	0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, 72, 96, 120*, 144, and 168 hrs postdose
Secondary	AUC	EDP-494 and metabolites	Day 1: 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15 hrs; Days 2, 3, 5, 7, 9, 12: 0 (Predose);Day 14: 0 (predose), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 24, 30, 36, 48, 60, 72, 96, 120, 144 and 168 hrs postdose
Secondary	Change from baseline in plasma HCV RNA (log10 IU/mL)		Baseline up to 14 days
Secondary	Amino Acid Changes in HCV polymerase NS5b		Baseline up to 3 months